CALC is trading 7.3% down at $0.92 as investors take profits following a sharp multi-day rally triggered by Bering Partners II disclosing a 6.9% activist-style stake.
- The recent surge was driven by speculative interest following the July 3 filing rather than fundamental changes for the no-revenue biotech.
- Today's price action reflects a normalization as the market reassesses the stock's valuation after the initial news-driven spike.
- Broader market weakness is likely contributing to the downward pressure on the shares.